Abstract
Background. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofetal protein upregulated in tumor cells during carcinogenesis. It has been linked to adverse clinical outcome in many malignancies.
This study was aimed to evaluate an immunohistochemical expression status of IMP3 in cutaneous basal cell carcinoma (BCC) and to correlate it with the Ki-67 index values.
Methods. Biopsy specimens from 32 cases of BCC were enrolled into this analysis. All samples were immunohistochemically stained for IMP3 (Clone 69.1) and Ki-67 antigen (Clone MIB-1).
Results. IMP3 showed a weak expression in 11 (34.4%) cases, a moderate expression in 11 (34.4%) cases, a strong expression in 5 (15.6%) cases, and negative staining in 5 (15.6%) cases. Among seven BCCs exhibiting aggressive-growth features, all but one showed weak reactivity. In contrast, all five BCCs manifesting strong IMP3 positivity consisted of the indolent-growth histologic subtypes. BCCs with infiltrative histomorphology did not appear to have a tendency towards more striking production of IMP3. There was no significant relationship between the IMP3 expression status and the proliferation status (Ki-67 ≤ 50% vs. Ki-67 > 50%) of the tumor tissue (p > 0.05).
Conclusions. The vast majority of cutaneous BCCs express IMP3, suggesting this oncoprotein is implicated in BCC carcinogenesis. However, more pronounced expression does not seem to be associated with aggressive-growth phenotype of BCC or higher proliferative activity of neoplastic cells.
References
Gong Y, Woda BA, Jiang Z. Oncofetal protein IMP3, a new cancer biomarker. Advances in Anatomic Pathology. 2014;21(3):191–200. Available from: https://doi.org/10.1097/PAP.0000000000000021
Burdelski C, Jakani-Karimi N, Jacobsen F, Möller-Koop C, Minner S, Simon R, et al. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncology Reports. 2018;39(1):3-12. Available from: https://doi.org/10.3892/or.2017.6072
Maržić D, Marijić B, Braut T, Janik S, Avirović M, Hadžisejdić I, et al. IMP3 protein overexpression is linked to unfavorable outcome in laryngeal squamous cell carcinoma. Cancers. 2021;13(17):4306. Available from: https://doi.org/10.3390/cancers13174306
Hakim SA, Abd Raboh NM, Shash LS. IMP3 immunohistochemical expression in inverted papilloma and inverted papilloma-associated sinonasal squamous cell carcinoma.Analytical Cellular Pathology. 2021;2021:6639834. Available from: https://doi.org/10.1155/2021/6639834
Bevanda Glibo D, Bevanda D, Vukojević K, Tomić S. IMP3 protein is an independent prognostic factor of clinical stage II rectal cancer. Scientific Reports. 2021;11(1):10844. Available from: https://doi.org/10.1038/s41598-021-90513-y
Sjekloča N, Tomić S, Mrklić I, Vukmirović F, Vučković L, Lovasić IB, et al. Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer. Medicine. 2020;99(7):e19091. Available from: https://doi.org/10.1097/MD.0000000000019091
Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clinica Chimica Acta. 2019;491:39–45. Available from: https://doi.org/10.1016/j.cca.2019.01.011
Bartoš V, Adamicová K, Kullová M, Péč M. Basal cell carcinoma of the skin - biological hehaviour of the tumor and a review of the most important molecular predictors of disease progression in pathological practice. Klin Onkol. 2011;24(1):8-17. Available from: https://pubmed.ncbi.nlm.nih.gov/21542271/
Bartoš V, Kullová M. Basal cell carcinoma of the skin with mixed histomorphology: a comparative study. Cesk Patol. 2016;52(4):222-226. Available from: https://pubmed.ncbi.nlm.nih.gov/27869450/
Mateoiu C, Pirici A, Bogdan FL. Immunohistochemical nuclear staining for p53, PCNA, Ki-67 and bcl-2 in different histologic variants of basal cell carcinoma. Rom J Morphol Embryol. 2011;52(1):315-319. Available from: https://pubmed.ncbi.nlm.nih.gov/21424069/
Tanese K. Diagnosis and management of basal cell carcinoma. Current Treatment Options in Oncology. 2019;20(2):13. Available from: https://doi.org/10.1007/s11864-019-0610-0
Sheen Y-S, Liao Y-H, Lin M-H, Chu C-Y, Ho B-Y, Hsieh M-C, et al. IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma. Journal of Investigative Dermatology. 2015;135(4):1065–1073. Available from: https://doi.org/10.1038/jid.2014.480
Ramirez‐Moreno E, Lozano‐Lozano M, O’Valle Ravassa F, Ramirez‐Tortosa C, Ruiz‐Villaverde R. Expression of IMP3 in a retrospective cohort of melanomas with selective lymph node biopsy. Dermatologic Therapy. 2020;33(6):e14413. Available from: https://doi.org/10.1111/dth.14413
Yu L, Xu H, Wasco MJ, Bourne PA, Ma L. IMP-3 expression in melanocytic lesions. Journal of Cutaneous Pathology. 2010;37(3):316–322. Available from: https://doi.org/10.1111/j.1600-0560.2009.01428.x
Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Modern Pathology. 2008;21(4):431–437. Available from: https://doi.org/10.1038/modpathol.3801016
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.